Analystreport

Castle Biosciences, Inc. (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report